Wegovy Pill Efficacy: OASIS 4 Trial Results Explained
Wegovy pill, also called oral semaglutide, was approved in the UK on the basis of the OASIS 4 phase 3 trial. The trial matters because it gives the clearest published picture of how much weight the tablet can help people lose, and how that compares with placebo.
What OASIS 4 showed
OASIS 4 followed adults for 68 weeks and found two figures that should always be read together. In the full-adherence analysis, people taking Wegovy pill lost 16.6% of their body weight on average compared with 2.7% on placebo. In the treatment-policy analysis, the figures were 13.6% and 2.2% respectively.
The second figure is lower because it counts participants who did not stay on treatment for the full study. Both numbers are useful, and both are correct.
Why the result matters
Averaged across the trial, that level of weight loss is clinically significant. It is large enough to be more than a lifestyle-only effect, but it is still an average, not a promise. Some people lose more, some less.
What the trial does not mean
It does not mean everyone will lose 16.6% of their weight. It does not mean the tablet is right for every patient. It also does not remove the need for side effect monitoring, review appointments, or prescriber guidance.
How to read the evidence
Oral semaglutide works through the same active ingredient as injectable semaglutide, but the tablet uses a different route into the body. That is why it deserves its own evidence page rather than being treated as a copy of the injection story.
For practical comparison, see the current price table and the dosing guide.
Bottom line
OASIS 4 supports Wegovy pill as a serious weight-loss treatment with real, measurable results. The cleanest way to describe it is simple: 16.6% with full adherence, 13.6% in the treatment-policy analysis, over 68 weeks.